Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
About this study
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Condition
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Sponsor
- Neurogen Biomarking LLC
Who can join
- Age
- 40 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 4
- Minimum age: 40 years
- Maximum age: 90 years
- Study condition: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
Exclusion 1
- Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Where
5 sites, 1 recruiting
Insigth Hospital and Medical Center Chicago
Chicago, Illinois, United States
Insight Hospital and Medical Center Dearborn
Dearborn, Michigan, United States
Insight Institute of Neurology and Neurosurgery
Flint, Michigan, United States
Memorial Healthcare Hospital
Owosso, Michigan, United States
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Contact
-
Ansam Eghzawi, MD
+18109410076 ansam@neurogenbiomarking.com
-
Elisabeth Thijssen, PhD
+16282788161 elisabeth@neurogenbiomarking.com
Potential match only. Final eligibility is determined by the study team.